U.S. markets closed

Lonza Group Ltd (LZAGF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
734.20+2.70 (+0.37%)
At close: 3:54PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close731.50
Open737.31
Bid0.00 x 0
Ask0.00 x 0
Day's Range733.70 - 741.82
52 Week Range507.00 - 741.82
Volume65
Avg. Volume265
Market Cap54.926B
Beta (5Y Monthly)0.46
PE Ratio (TTM)56.48
EPS (TTM)13.00
Earnings DateN/A
Forward Dividend & Yield3.32 (0.45%)
Ex-Dividend DateMay 10, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Moderna Inks COVID-19 Vaccine Production Agreement with Lonza
    SmarterAnalyst

    Moderna Inks COVID-19 Vaccine Production Agreement with Lonza

    Biotechnology company Moderna Inc. (MRNA) has inked an additional drug substance manufacturing agreement with Lonza. Per the terms of the agreement, a new production line will be set up at Lonza’s Geleen facility in the Netherlands, which will supply 300 million doses of Moderna’s booster variant vaccine candidate which is yet to receive approval. Moderna also has a drug substance supply agreement with ROVI in Spain and expects to supply about 600 million doses each year in the E.U. Both of thes

  • Moderna, Lonza Team Up To Produce New Drug Substance for COVID-19 Vaccine Doses
    Benzinga

    Moderna, Lonza Team Up To Produce New Drug Substance for COVID-19 Vaccine Doses

    Moderna Inc (NASDAQ: MRNA) is gearing up to halve the dose of its COVID-19 vaccine so that it can also be used to combat variants and inoculate children. It has entered into a deal with Lonza Group (OTC: LZAGF) for a new drug substance production line in Geleen, Netherlands, which will have the capacity to make ingredients for up to 300 million doses annually at 50 micrograms per dose. The new agreement with Lonza will increase drug substance production in Europe by the fourth quarter of 2021. C

  • Reuters

    UPDATE 2-Moderna plans mix of COVID-19 vaccine doses with new Lonza deal

    Moderna is gearing up to halve the dose of its COVID-19 vaccine, the U.S. drugmaker said on Wednesday, so that it can also be used to combat variants and inoculate children. It has agreed a deal with Swiss-based drugmaker Lonza which said a new drug substance production line in Geleen, Netherlands, will have capacity to make ingredients for up to 300 million doses annually at 50 micrograms per dose. "We're assuming that as of 2022, we are going to have a mix of dose levels on the market," a spokeswoman for Moderna said, following the announcement of Lonza's new production.